Payment overview · 2025
General Payments
$381.11
19 reported records · 10 companies
Healthcare provider profile · identity verified
David Roy Miller, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AGOURA HILLS, CA · NPI 1912958257
Verified facts
What the public records show
CMS Open Payments records show David Roy Miller, M.D. received $381.11 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.30 | 35.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.82 | 15.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.60 | 11.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.00 | 7.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.65 | 6.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.42 | 5.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.90 | 5.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.86 | 5.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.39 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.17 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.11 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.82 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.60 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 46 |
| Gabapentin | Gabapentin | 156 | 43 |
| Eliquis | Apixaban | 128 | 20 |
| Losartan Potassium | Losartan Potassium | 116 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 27 |
| Alprazolam | Alprazolam | 102 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 30 |
| Metformin Hcl Er | Metformin Hcl | 91 | 33 |
| Omeprazole | Omeprazole | 90 | 24 |
| Prednisone | Prednisone | 87 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 24 |
| Trazodone Hcl | Trazodone Hcl | 78 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 18 |
| Liothyronine Sodium | Liothyronine Sodium | 64 | 20 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 62 | 17 |
| Lisinopril | Lisinopril | 61 | 12 |
| Sertraline Hcl | Sertraline Hcl | 60 | 15 |
| Furosemide | Furosemide | 59 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 18 |
| Allopurinol | Allopurinol | 56 | 16 |
| Potassium Chloride | Potassium Chloride | 56 | 12 |
| Famotidine | Famotidine | 51 | 17 |
| Lorazepam | Lorazepam | 49 | 13 |
| Valsartan | Valsartan | 49 | suppressed |
| Cefdinir | Cefdinir | 47 | 38 |
| Ezetimibe | Ezetimibe | 47 | 17 |
| Valacyclovir | Valacyclovir Hcl | 47 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Diazepam | Diazepam | 39 | 12 |
| Azithromycin | Azithromycin | 37 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 20 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Mupirocin | Mupirocin | 35 | 27 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 32 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Anastrozole | Anastrozole | 32 | 11 |
| Latanoprost | Latanoprost | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 19 |
| Budesonide Dr | Budesonide | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | 11 |
| Meloxicam | Meloxicam | 29 | 13 |
| Methylprednisolone | Methylprednisolone | 29 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 20 |
| Finasteride | Finasteride | 25 | suppressed |
| Progesterone | Progesterone, Micronized | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Carvedilol | Carvedilol | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Jinteli | Norethindrone Ac/Eth Estradiol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 13 |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lyllana | Estradiol | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Jublia | Efinaconazole | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.11 · 19 records | Novo Nordisk Inc | AIRSUPRA, Cologuard Collection Kit, FREESTYLE LIBRE 3, Ozempic, REXULTI, Rybelsus, Sunosi, UBRELVY, VOQUEZNA, VYNDAMAX, Wegovy, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error